# US 2019/0375748 A1 · Bicyclic heterocycle compounds and their uses in therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375748 A1
- Document ID: US20190375748A1
- Status: Published application
- Kind: A1
- Application number: 16/409,364
- Filed: 2019-05-10
- Published: 2019-12-12
- Earliest claimed: 2011-04-21
- Assignees: Astex Therapeutics Limited
- Applicants: Astex Therapeutics Limited
- Inventors: Alison Jo-Anne WOOLFORD; Steven HOWARD; Ildiko Maria BUCK; Gianni CHESSARI; Christopher Norbert JOHNSON; Emiliano TAMANINI; James Edward Harvey DAY; Elisabetta CHIARPARIN; Thomas Daniel HEIGHTMAN; Martyn FREDERICKSON; Charlotte Mary GRIFFITHS-JONES
- Web page: https://patentgrep.com/patent/US20190375748A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/497: containing further heterocyclic rings
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 471/10: Spiro-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 487/10: Spiro-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to bicyclic heterocycle compounds of formula (I): or tautomeric or stereochemically isomeric forms, N-oxides, pharmaceutically acceptable salts or the solvates thereof; wherein R1, R2a, R2b, R3a, R3b, R5, R6, R7, R8, R9, p and E are as defined herein; to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

## Claims

### Claim 1

A pharmaceutical composition comprising a compound of formula (I):
or a tautomeric or stereochemically isomeric form, N-oxide, pharmaceutically acceptable salt or solvate thereof; wherein
Ring E represents phenyl, pyrimidinyl, pyridazinyl, pyridyl, or pyridinonyl;
G and J are independently selected from C and N;
Q is CR4 or N;
R1 is selected from C1-4 alkyl, C2-4 alkenyl and —(CH2)s—C3-8 cycloalkyl, wherein said C1-4 alkyl, C2-4 alkenyl, and C3-8 cycloalkyl may be optionally substituted by one or more Ra groups;
Ra is selected from halogen, —OH and —O—C1-6alkyl;
R2a and R2b are independently selected from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, —C(═O)NH(2-q)(C1-6 alkyl)q, —(CH2)s-(3-12 membered heterocyclyl), and —(CH2)s—C3-12 carbocyclyl, or R2a and R2b groups, together with the carbon atom to which they are attached, can join to form a 3-10 membered saturated carbocyclyl or heterocyclyl group, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, heterocyclyl and carbocyclyl groups may be optionally substituted by one or more Rb groups;
R3a and R3b are independently selected from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, —C(═O)NH(2-q)(C1-6 alkyl)q, —(CH2)s-(3-12 membered heterocyclyl), —(CH2)s—C3-12 carbocyclyl, —C(═O)-(3-12 membered heterocyclyl), and —C(═O)—C3-12 carbocyclyl,
or R3a and R3b groups, together with the carbon atom to which they are attached, can join to form a 3-10 membered saturated carbocyclyl or heterocyclyl group, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, heterocyclyl and carbocyclyl groups may be optionally substituted by one or more Rb groups;
R4 is selected from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, —C(═O)NH(2-q)(C1-6 alkyl)q, —(CH2)s-(3-12 membered heterocyclyl), —(CH2)s—C3-12 carbocyclyl, —C(═O)-(3-12 membered heterocyclyl), and —C(═O)—C3-12 carbocyclyl, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, heterocyclyl and carbocyclyl groups may be optionally substituted by one or more Rb groups;
R5 is selected from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, —(CH2)s—C3-8 cycloalkyl and —(CH2)s—C3-8 cycloalkenyl, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl and C3-8 cycloalkenyl may be optionally substituted by one or more Ra groups;
R6 and R7 are independently selected from hydrogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, —Y—C3-12 carbocyclyl, —Z-(3-12 membered heterocyclyl), —(CRxRy)s—O—Rz, —O—(CRxRy)n—ORz, (CH2)s—CN, —S(O)q—Rx, —C(═O)Rx, —C(═S)Rx, —C(═N)Rx, —(CRxRy)s—C(═O)ORz, —(CRxRy)s—O—C(═O)—Rz, —(CRxRy)s—C(═O)NRxRy, —(CH2)s—NRxC(═O)Ry, —(CH2)s—OC(═O)NRxRy, —(CH2)s—NRxC(═O)ORy, —(CH2)s—NRxRy, —NRx—(CH2)s—Rz, —(CRxRy)s—C(═S)NRz, —(CRxRy)s—C(═N)NRz, (CH2)s—O—C(═O)—C1-4alkyl-NRxRy, —(CH2)s—NRx—(CH2)n—O—C(═O)—Rz, —(CH2)s—NRx—(CH2)s—SO2—Ry, —(CH2)s—NH—SO2—NRxRy and —(CH2)s—SO2NRxRy groups,
or R6 and R7 groups, together with the carbon atom to which they are attached, can join to form a 3-10 membered fully or partially saturated carbocyclyl or heterocyclyl group, which may be optionally fused to a 5-6 membered aromatic carbocyclyl or heterocyclyl ring, wherein said C1-8 alkyl, C2-8 alkenyl and C2-8 alkynyl groups may be optionally substituted by one or more Rb groups and wherein said carbocyclyl and heterocyclyl groups may be optionally substituted by one or more Rb groups;
R8 and R9 are independently selected from hydrogen, halogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, —Y—C3-12 carbocyclyl, —Z-(3-12 membered heterocyclyl), —(CRxRy)s—O—Rz, —O—(CRxRy)n—ORz, ═O, ═S, nitro, Si(Rx)4, —(CH2)s—CN, —S(O)q—(CRxRy)s—Rz, —C(═O)Rx, —C(═S)Rx, —C(═N)R, —(CRxRy)s—C(═O)ORz, —(CRxRy)s—O—C(═O)—Rz, —(CRxRy)s—C(═O)NRxRy, —(CH2)s—NRxC(═O)Ry, —(CH2)s—OC(═O)NRxRy, —(CH2)s—NRxC(═O)ORy, —(CH2)s—NRxRy, —NRx—(CH2)s—Rz, —(CRxRy)s—C(═S)NRz, —(CRxRy)s—C(═N)NRx, —S(O)(═NRx)Ry, —(CH2)s—O—C(═O)—C1-4alkyl-NRxRy, —(CH2)s—NRx—(CH2)n—O—C(═O)—Rz, —(CH2)s—NRx—(CH2)s—SO2—Ry, —(CH2)s—NH—SO2—NRxRy, —(CH2)s—SO2NRxRy groups and —P(═O)(Rx)2, wherein said C1-8 alkyl, C2-8 alkenyl and C2-8 alkynyl groups may be optionally substituted by one or more Rb groups and wherein said carbocyclyl and heterocyclyl groups may be optionally substituted by one or more Rb groups;
Rb is independently selected from halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, —(CH2)s—C3-8 cycloalkyl, —(CH2)s—C3-8 cycloalkenyl, —(CH2)s-phenyl, —(CH2)s-(4-7 membered saturated heterocyclyl), —(CRxRy)s—O—Rz, —O—(CRxRy)n—ORz, haloC1-6 alkyl, haloC1-6 alkoxy, C1-6 alkanol, ═O, ═S, nitro, Si(Rx)4, —(CH2)s—CN, —S(O)q—Rx, —C(═O)Rx, —(CRxRy)s—C(═O)ORz, —(CRxRy)s—O—C(═O)—Rz, —(CRxRy)s—C(═O)NRxRy, —(CH2)s—NRxC(═O)Ry, —(CH2)s—OC(═O)NRxRy, —(CH2)s—NRxC(═O)ORy—(CH2)s—NRxRy, —NRx—(CH2)s—Rz, —(CH2)s—O—C(═O)—C1-4alkyl-NRxRy, —(CH2)s—NRx—(CH2)n—O—C(═O)—Rz, —(CH2)s—NRx—(CH2)s—SO2—Ry, —(CH2)s—NH—SO2—NRxRy, —(CH2)s—SO2NRxRy groups and —P(═O)(Rx)2, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, C3-8 cycloalkenyl and heterocyclyl groups may be optionally substituted by one or more Rx groups;
Rx, Ry and Rz independently represent halogen, hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, —(CH2)s—C3-8 cycloalkyl, —(CH2)s—C3-8 cycloalkenyl, —(CH2)s-phenyl, —(CH2)s-(4-7 membered saturated heterocyclyl), C1-6 alkanol optionally substituted with one or more halo, —C(═O)OC1-6 alkyl, hydroxy, C1-6 alkoxy, haloC1-6 alkyl, —(CH2)n—O—C1-6alkyl, —C(═O)—(CH2)n—C1-6 alkoxy, —C(═O)—C1-6alkyl, —(CH2)s—CN, C1-6 alkyl-N(H)2-q(C1-6alkyl)q, —N(H)2-q(C1-6alkyl)q, —C(═O)—N(H)2-q(C1-6alkyl)q, —(CH2)s—NH—SO2—N(H)2-q (C1-6alkyl)q, —(CH2)s—N(C1-4alkyl)-SO2—N(H)2-q(C1-6alkyl)q or —(CH2)s—O—C(═O)—C1-4alkyl-N(H)2-q (C1-6alkyl)q, and when attached to nitrogen, carbon, silicon or phosphorus atom Rx and Ry may join to form a 3-7 membered ring optionally containing one or two additional heteroatoms selected from O, N, S and oxidised forms of N or S;
Y and Z are independently selected from a bond, —(CRxRy)m—, —C(═CRx)—, —C(═O)—, —NR, —C(═O)NRx—, —NRxC(═O)—, —(CRxRy)q—O—, —O—(CRxRy)q—, —S(O)2—NH, NH—S(O)2— and —S(O)q—;
s independently represents an integer from 0-4;
n independently represents an integer from 1-4;
p independently represents an integer from 0-4;
q represents an integer from 0-2; and
m represents an integer from 1-2.

### Claim 2 (depends on 1)

A pharmaceutical composition as defined in claim 1, wherein Q represents N.

### Claim 3 (depends on 1)

A pharmaceutical composition as defined in claim 1, wherein ring E represents pyridyl, pyridazinyl or phenyl.

### Claim 4 (depends on 1)

A pharmaceutical composition as defined in claim 1, wherein R1 represents methyl.

### Claim 5 (depends on 1)

A pharmaceutical composition as defined in claim 1, wherein R2a and R2b are hydrogen.

### Claim 6 (depends on 1)

A pharmaceutical composition as defined in claim 1, wherein:
(i) R3a and R3b are independently selected from hydrogen, C1-6 alkyl, —C(═O)NH(2-q)(C1-6 alkyl)q, —(CH2)s-(3-12 membered heterocyclyl), —(CH2)s—C3-12 carbocyclyl, —C(═O)-(3-12 membered heterocyclyl), and —C(═O)—C3-12 carbocyclyl wherein said C1-6 alkyl, heterocyclyl and carbocyclyl groups may be optionally substituted by one or more Rb groups; or
(ii) one of R3a and R3b represents hydrogen and the other represents:
C1-6 alkyl, optionally substituted by halogen, —(CRxRy)s—O—Rz; —(CH2)s—NRxC(═O)Ry);
—C(═O)NH(2-q)(C1-6 alkyl)q;
—(CH2)s-(3-6 membered heterocyclyl); or
—C(═O)-(3-6 membered heterocyclyl)
wherein said heterocyclyl groups may be optionally substituted by one or more Rb groups; or
(iii) R3b is hydrogen, and R3a is —CH2-(6 membered saturated heterocyclyl), wherein said heterocyclyl group may be optionally substituted by one or more Rb groups; or
(iv) R3b is hydrogen, and R3a is —CH2-(4-morpholinyl) optionally substituted by one or more Rb groups.

### Claim 7 (depends on 1)

A pharmaceutical composition as defined in claim 1, wherein R5 represents hydrogen.

### Claim 8 (depends on 1)

A pharmaceutical composition as defined in claim 1, wherein;
(i) R6 and R7 are independently selected from hydrogen, C1-6 alkyl, —Y—C3-6 carbocyclyl; —Z-(3-12 membered heterocyclyl); —(CRxRy)s—C(═O)ORz; and —(CRxRy)s—O—Rz; or
(ii) R6 and R7 are both methyl; or
(iii) R6 and R7 groups, together with the carbon atom to which they are attached, join to form a 3-6 membered fully saturated carbocyclyl or heterocyclyl group, and which may be optionally fused to a 5-6 membered aromatic carbocyclyl or heterocyclyl ring, wherein said carbocyclyl and heterocyclyl groups may be optionally substituted by 1, 2 or 3 Rb groups.

### Claim 9 (depends on 1)

A pharmaceutical composition as defined in claim 1, wherein p is 0, or p is 1 and R8 is selected from halogen, ═O, C1-6 alkyl and —(CRxRy)s—O—Rz.

### Claim 10 (depends on 1)

A pharmaceutical composition as defined in claim 1, wherein:
(i) R9 is selected from halogen, —(CH2)s—CN, C1-8 alkyl, —Y—C3-12 carbocyclyl, —Z-(3-12 membered heterocyclyl), —S(O)q—(CRxRy)s—Rz and —(CH2)s—SO2NRxRy, wherein said carbocyclyl groups or heterocyclyl groups may be optionally substituted by one or more Rb groups; or
(ii) R9 is selected from chlorine, fluorine, bromine, —CN, methyl, ethyl, propyl, isobutyl, butyl, —(CH2)2—CH(CH3)2), —CH2-phenyl, —CF2-phenyl, —CH(CH3)-phenyl, —CH(OCH3)-phenyl, —C(═CH2)-phenyl, —O-phenyl, —SO2-phenyl, —C(═O)-phenyl, —CF2-cyclopropyl, —CF2-cyclobutyl, —CF2—CH2-cyclobutyl, -cyclopentyl, -cyclopentenyl, —CH2-cyclohexyl, cyclohexyl, cyclohexenyl, -pyrazolyl, -furanyl, -thienyl, -oxadiazolyl, -tetrazolyl, -benzofuranyl, —CH2-pyrrolidinyl, —SO2CH3, —SO2—CH2CH(CH3)2, —SO2—CH2-phenyl, and —SO2N(CH3)2, wherein said phenyl, pyrazolyl, furanyl, thienyl, oxadiazolyl, tetrazolyl, benzofuranyl or pyrrolidinyl groups may be optionally substituted by one or more Rb groups; or
(iii) R9 is selected from —(CRxRy)1-2-cyclopropyl, —(CRxRy)-cyclobutyl, —(CRxRy)-phenyl, ethyl, propyl or butyl each of which may be optionally substituted by one or more halogen atoms and wherein Rx and Ry are independently selected from hydrogen and fluorine; or
(iv) R9 is —CH2-(4-fluorophenyl).

### Claim 11 (depends on 1)

A pharmaceutical composition as defined in claim 1, wherein the compound is a compound of formula (Ic):
or a tautomeric or stereochemically isomeric form, N-oxide, pharmaceutically acceptable salt or solvate thereof, wherein
A is selected from CR8 and N;
U is selected from CR8 and N; and
V is selected from CR9 and N;
provided that no more than two of A, U, and V are nitrogen.

### Claim 12 (depends on 1)

A pharmaceutical composition as defined in claim 1, wherein the compound is a compound of formula (Ii)a or (Ii)b:
or a tautomeric or stereochemically isomeric form, N-oxide, pharmaceutically acceptable salt or solvate thereof.

### Claim 13 (depends on 1)

A pharmaceutical composition as defined in claim 1, wherein the compound is a compound of formula (Ik)a or (Ik)b:
or a tautomeric or stereochemically isomeric form, N-oxide, pharmaceutically acceptable salt or solvate thereof.

### Claim 14 (depends on 1)

A pharmaceutical composition as defined in claim 1, wherein the compound is a compound of formula (Im) or (In):
or a tautomeric or stereochemically isomeric form, N-oxide, pharmaceutically acceptable salt or solvate thereof.

### Claim 15 (depends on 1)

A pharmaceutical composition as defined in claim 1, wherein the compound is the free base of a compound selected from Examples 1 to 266 or a tautomeric or stereochemically isomeric form, N-oxide, pharmaceutically acceptable salt or the solvate thereof.

### Claim 16 (depends on 1)

A pharmaceutical composition as defined in claim 1, or a tautomeric or stereochemically isomeric form, N-oxide, pharmaceutically acceptable salt or solvate thereof, in combination with one or more therapeutic agents.
